Patch Photostability: When the Pouch Really Needs a Light Barrier

A patch does not automatically need a foil pouch. The packaging decision should follow light-exposure data. ICH Q1B uses a sequence: test the product fully exposed, then in the immediate pack if needed, and finally in the marketing pack until the results show adequate protection.

ICH Q1B addresses photostability of new drug substances and products. The same experimental logic can inform other patch types, but the formal regulatory scope, acceptance criteria and test plan depend on product classification.

The packaging question behind the test

Light can affect more than an active ingredient. A patch matrix may discolour, a botanical extract may oxidise, an adhesive may change, or an opaque backing may protect the formula while a clear release liner does not. Guessing at the pouch can lead to two expensive mistakes: insufficient protection or a high-barrier laminate that the product never needed.

ICH Q1B treats photostability as part of stress testing. The goal is to find out whether light produces unacceptable change and, when it does, whether the immediate or marketing pack prevents it.

The decision path

Step 1: expose the patch outside its immediate pack

Begin with the drug product directly exposed, presented so that light reaches a representative area. Use a temperature control or a dark control so that a heat effect is not mistaken for a light effect.

For confirmatory work, ICH Q1B specifies overall illumination of at least 1.2 million lux hours and integrated near-ultraviolet energy of at least 200 watt hours per square metre. The exposure can be measured with calibrated radiometers or lux meters, or a validated actinometric system.

Step 2: decide whether the observed change is acceptable

The applicant defines and justifies acceptable change. Evaluation should use methods capable of detecting photolytic degradation and should consider physical properties as well as assay and degradants.

For a patch, record observations that can be lost in a single “pass” entry: colour on the backing and matrix, adhesive bleed, crystal formation, curling, liner release, odour and any change in the relevant delivery test. Use pre-defined acceptance criteria where the attribute affects quality or use.

Step 3: repeat in the immediate pack if protection is needed

If direct exposure causes unacceptable change, test the patch in its immediate pack. This is where pouch construction becomes an experimental variable rather than a purchasing preference.

A transparent polymer pouch, a printed high-barrier film and an aluminium-containing laminate may provide different light protection. Barrier against moisture or oxygen is a separate property, so a good photostability result does not by itself establish the full pack specification.

Step 4: test the marketing pack when the immediate pack is not enough

ICH Q1B recommends progressing to the marketing pack when necessary. For a patch, that could include a carton that blocks light around a partly protective pouch. If protection depends on the carton, distribution and consumer instructions must preserve that configuration.

Testing can stop when the results demonstrate adequate protection. The point is not to run every configuration; it is to identify the simplest pack that keeps the product within justified limits.

What the lab set-up should record

One batch, with a reason to add more

ICH Q1B normally uses one drug-product batch during development and confirmation when the product is clearly photostable or photolabile. If the result is equivocal, testing of up to two additional batches is recommended.

“One batch” does not make sample control optional. Test units should represent the formulation and pack under evaluation. If two pouch suppliers, ink coverages or backing colours are being compared, identify them as separate variables and avoid pooling results.

Four outcomes and what they mean

• No unacceptable change outside the pouch: light protection may not be the factor that drives pouch opacity, although moisture, oxygen and seal needs still may.
• Change outside the pouch, none in the immediate pack: the tested pouch provides adequate light protection for the assessed attributes.
• Change in the immediate pack, none in the marketing pack: the carton or secondary pack is part of the protective system and should be controlled accordingly.
• Change remains in the marketing pack: formulation, backing, pouch or secondary packaging needs more development before the proposed presentation is supported.

Short answers for packaging teams

Is a foil pouch always safer?
It can provide strong light and barrier protection, but “safer” depends on the product’s failure mechanisms. Extra layers can add cost and complicate recyclability. Use the test result to decide.

Can the carton replace an opaque pouch?
Only if testing supports the marketed system and the carton remains with the product during the period when protection is needed.

Does ICH Q1B replace long-term stability?
No. Photostability is part of stress testing. Shelf-life support still relies on the broader stability programme and justified specifications.

A useful OEM brief to Henan Hanmeng Bio-Tech states the light-sensitive ingredients, backing colour, proposed pouch structures, market carton and target shelf life. That gives the laboratory a real comparison instead of a yes-or-no request for “foil.”

Source

• ICH Q1B: Photostability Testing of New Drug Substances and Products, especially the general procedure and drug-product decision sequence.
• ICH Q1A(R2): Stability Testing of New Drug Substances and Products, for the wider stability programme.